<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750332</url>
  </required_header>
  <id_info>
    <org_study_id>CT-002</org_study_id>
    <secondary_id>PXL225421</secondary_id>
    <nct_id>NCT02750332</nct_id>
  </id_info>
  <brief_title>Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)</brief_title>
  <official_title>A Single Center, Single-Dose, Open-Label, Randomized Study to Compare the Bioavailability of an Oral Test Formulation Containing Nitisinone 10 mg in at Least 16 Healthy Male and Female Subjects Under Fasting and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cycle Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cycle Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the bioavailability of the Test Product, Nitisinone&#xD;
      10 mg Tablet, under fasting and fed conditions (food-effect).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aim is to conduct a randomized, single dose, two-period crossover&#xD;
      bioavailability study in at least 16 healthy male and female subjects at a single study&#xD;
      center to evaluate the in vivo performance of Test Product, Nitisinone 10 mg Tablet, under&#xD;
      fasting and fed conditions.&#xD;
&#xD;
      The study in healthy male and female volunteers is designed to establish a pharmacokinetic&#xD;
      (PK) profile under fed and fasting conditions for the orally administered Test Product,&#xD;
      Nitisinone 10 mg Tablets.&#xD;
&#xD;
      A total of 20 healthy female and male volunteers (age 18 to 55 years old) will be entered&#xD;
      into the study. Volunteers will be determined to be free of significant medical conditions as&#xD;
      assessed by medical history, physical examination, and blood and urine tests. Volunteers will&#xD;
      be randomly allocated to receive the Test Product under fasting or fed conditions.&#xD;
&#xD;
      There will be a minimum 23 calendar days washout between treatments. Blood samples will be&#xD;
      collected at pre-dose (0 hours) and at 15 minutes, 30 minutes, 1 hour, 2 hours, 2 hours and&#xD;
      30 minutes, 3 hours, 3 hours and 30 minutes, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10&#xD;
      hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours post-dose&#xD;
      (total: 21 samples per treatment period).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 - 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))</measure>
    <time_frame>0 - 120 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))</measure>
    <time_frame>0 - 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))</measure>
    <time_frame>0 - 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0 - 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (λz)</measure>
    <time_frame>0 - 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>0 - 120 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hereditary Tyrosinemia, Type I</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence A (Fed) - B (Fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence B (Fasted) - A (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>A single oral dose of Nitisinone 10 mg Tablet will be administered.</description>
    <arm_group_label>Treatment Sequence A (Fed) - B (Fasted)</arm_group_label>
    <arm_group_label>Treatment Sequence B (Fasted) - A (Fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects, 18 to 55 years (both inclusive) at signing of&#xD;
             informed consent.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 and 30 kg/m2 (inclusive).&#xD;
&#xD;
          -  Body mass not less than 50 kg.&#xD;
&#xD;
          -  Medical history, vital signs, physical examination, standard 12-lead electrocardiogram&#xD;
             (ECG) and laboratory investigations must be clinically acceptable or within laboratory&#xD;
             reference ranges for the relevant laboratory tests, unless the investigator considers&#xD;
             the deviation to be irrelevant for the purpose of the study.&#xD;
&#xD;
          -  Non-smokers.&#xD;
&#xD;
          -  Females, if:&#xD;
&#xD;
        Of childbearing potential, the following conditions are to be met:&#xD;
&#xD;
          -  Negative pregnancy test If this test is positive, the subject will be excluded from&#xD;
             the study. In the rare circumstance that a pregnancy is discovered after the subject&#xD;
             received IMP, every attempt must be made to follow her to term.&#xD;
&#xD;
          -  Not lactating&#xD;
&#xD;
          -  Abstaining from sexual activity (if this is the usual lifestyle of the subject) or&#xD;
             must agree to use an accepted method of contraception, and agree to continue with the&#xD;
             same method throughout the study Examples of reliable methods of contraception include&#xD;
             non-hormonal intrauterine device, and barrier methods combined with an additional&#xD;
             contraceptive method. In this study the concomitant use of hormonal contraceptives is&#xD;
             NOT allowed. Other methods, if considered by the investigator as reliable, will be&#xD;
             accepted.&#xD;
&#xD;
          -  Written consent given for participation in the study.&#xD;
&#xD;
          -  Subjects must be willing to consume the meal prescribed with administration of the IMP&#xD;
             in full and within the required time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional&#xD;
             or intellectual problems likely to limit the validity of consent to participate in the&#xD;
             study or limit the ability to comply with protocol requirements.&#xD;
&#xD;
          -  Current alcohol use &gt; 21 units of alcohol per week for males and &gt; 14 units of alcohol&#xD;
             per week for females.&#xD;
&#xD;
          -  Consumption of more than 5 cups of coffee (or equivalent amounts of caffeine) per day.&#xD;
&#xD;
          -  Regular exposure to substances of abuse (other than alcohol) within the past year.&#xD;
&#xD;
          -  Use of any medication, prescribed or over-the-counter or herbal remedies, within 2&#xD;
             weeks before the first administration of investigational medicinal product (IMP)&#xD;
             except if this will not affect the outcome of the study in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
        In this study the concomitant use of hormonal contraceptives is NOT allowed.&#xD;
&#xD;
          -  Participation in another study with an experimental drug, where the last&#xD;
             administration of the previous IMP was within 8 weeks (or within 10 elimination&#xD;
             half-lives for chemical entities or 2 elimination half-lives for antibodies or&#xD;
             insulin), whichever is the longer) before administration of IMP in this study, at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
          -  Treatment within the previous 3 months before the first administration of IMP with any&#xD;
             drug with a well-defined potential for adversely affecting a major organ or system.&#xD;
&#xD;
          -  A major illness during the 3 months before commencement of the screening period.&#xD;
&#xD;
          -  History of hypersensitivity or allergy to the IMP or its excipients or any related&#xD;
             medication.&#xD;
&#xD;
          -  History of bronchial asthma or any other bronchospastic disease.&#xD;
&#xD;
          -  History of convulsions.&#xD;
&#xD;
          -  History of porphyria.&#xD;
&#xD;
          -  Relevant history or laboratory or clinical findings indicative of acute or chronic&#xD;
             disease, likely to influence study outcome.&#xD;
&#xD;
          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the&#xD;
             first administration of IMP.&#xD;
&#xD;
          -  Diagnosis of hypotension made during the screening period.&#xD;
&#xD;
          -  Diagnosis of hypertension made during the screening period or current diagnosis of&#xD;
             hypertension.&#xD;
&#xD;
          -  Resting pulse of &gt; 100 beats per minute or &lt; 40 beats per minute during the screening&#xD;
             period, either supine or standing.&#xD;
&#xD;
          -  Positive testing for human immunodeficiency virus (HIV), Hepatitis B and Hepatitis C.&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse. In case of a positive result the urine&#xD;
             screen for drugs of abuse may be repeated once at the discretion of the investigator.&#xD;
&#xD;
          -  Positive urine screen for tobacco use.&#xD;
&#xD;
          -  Positive pregnancy test.&#xD;
&#xD;
          -  Female subjects that are pregnant or breastfeeding.&#xD;
&#xD;
          -  Difficulty in swallowing.&#xD;
&#xD;
          -  Any specific investigational product safety concern.&#xD;
&#xD;
          -  Vulnerable subjects, e.g. persons in detention.&#xD;
&#xD;
          -  Subjects with current keratopathy, or other clinically significant abnormalities found&#xD;
             by slit-lamp examination (cataracts) at the discretion of the investigator.&#xD;
&#xD;
          -  Concomitant use of medications that are metabolized by CYP2C9 (ibuprofen, diclofenac&#xD;
             and indomethacin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Nell</last_name>
    <role>Principal Investigator</role>
    <affiliation>+27 51 410 3046</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <results_first_submitted>October 19, 2016</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2016</results_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HT-1</keyword>
  <keyword>Tyrosinemia</keyword>
  <keyword>Nitisinone</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Food-Effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tyrosinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence A (Fed) - B (Fasted)</title>
          <description>Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg Tablet will be administered.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence B (Fasted) - A (Fed)</title>
          <description>Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg Tablet will be administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>0 - 120 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product (Fasted)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Test Product (Fed)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1168.23" spread="22.2"/>
                    <measurement group_id="O2" value="1054.32" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))</title>
        <time_frame>0 - 120 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product (Fasted)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Test Product (Fed)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71441.92" spread="26.4"/>
                    <measurement group_id="O2" value="67242.59" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))</title>
        <time_frame>0 - 72 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product (Fasted)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Test Product (Fed)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52976.29" spread="24.0"/>
                    <measurement group_id="O2" value="49762.02" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))</title>
        <time_frame>0 - 120 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product (Fasted)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Test Product (Fed)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100007.01" spread="34.5"/>
                    <measurement group_id="O2" value="90749.55" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>0 - 120 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product (Fasted)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Test Product (Fed)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="6.00" lower_limit="2.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant (λz)</title>
        <time_frame>0 - 120 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product (Fasted)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Test Product (Fed)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>1/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="26.9"/>
                    <measurement group_id="O2" value="0.012" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Half-life (t1/2)</title>
        <time_frame>0 - 120 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product (Fasted)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Test Product (Fed)</title>
            <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life (t1/2)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.40" spread="26.9"/>
                    <measurement group_id="O2" value="59.22" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the period of the study (November 2015 - December 2015).</time_frame>
      <desc>20 subjects were entered in to the study and randomized to either fasted or fed treatment sequence before first administration of the Investigational Medicinal Product (IMP). One subject withdrew from the study after Treatment Period 1 (Fasted) due to personal reasons. As a result, only 19 subjects completed the fed treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Product (Fasted)</title>
          <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fasted conditions.</description>
        </group>
        <group group_id="E2">
          <title>Test Product (Fed)</title>
          <description>A single oral dose of Nitisinone 10 mg Tablet will be administered under fed conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Itching Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Price</name_or_title>
      <organization>Cycle Pharmaceuticals Ltd</organization>
      <phone>+44 1223 803638</phone>
      <email>james.price@cyclepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

